SRES-285-119
Submitted in the Senate, considered, and agreed to without amendment and with a preamble by Unanimous Consent. (consideration: CR S3442; text: CR S3441)
Sponsored by Lindsey Graham (R-SC)
What it does
This resolution designates July 16, 2025, as "Glioblastoma Awareness Day." It encourages public awareness of glioblastoma — the most common and deadly malignant brain tumor — and expresses Senate support for research, improved treatments, and molecular biomarker testing. It does not appropriate funds, create programs, or impose any legal requirements.
Who benefits
Patients currently diagnosed with glioblastoma (estimated 13,000+ new diagnoses in 2025), their families, caregivers, and patient advocacy organizations who gain a platform for public attention. Researchers and institutions — such as the National Cancer Institute's Glioblastoma Therapeutics Network — may benefit from increased public and legislative visibility for the disease. Nonprofit organizations focused on brain cancer awareness may see increased donations or engagement.
Who is hurt
No group is directly harmed by this resolution. There are no mandates, spending changes, or regulatory effects. Indirectly, other disease advocacy communities compete for limited congressional attention and awareness-day designations, though this is a diffuse and minimal effect.
Supporters argue
Supporters argue that glioblastoma's devastating statistics — a 6.9% five-year survival rate, a median survival of only 8 months, and more than 10,000 deaths per year — justify dedicated public attention. They contend that awareness days have historically helped mobilize research funding and patient advocacy, and note that only 5 drugs and 1 medical device have been FDA-approved for glioblastoma since the 1920s despite its severity, underscoring the urgent need for greater public and scientific focus.
Opponents argue
Opponents might argue that congressional awareness-day resolutions are largely symbolic and do not translate into measurable improvements in research funding, treatment development, or patient outcomes. They contend that the Senate's limited floor time could be directed toward binding legislation — such as appropriations for the National Cancer Institute or the Glioblastoma Therapeutics Network — that would produce concrete, enforceable results rather than a non-binding declaration with no legal effect.